Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Yimin Zou
University of California, San Diego, Department: None
Should you be removed from our database? Contact us at [email protected]. Read more below.
VersaChem, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Zou is the founder and acting CEO, holds (b)(4) equity interest in VersaChem. VersaChem’s mission is to discover novel small molecule drugs for neurological diseases and cancer. Company uses published information about the components and some of the signaling mechanisms discovered by scientists that are not patentable. The grant is to discover novel signaling and cell biological mechanisms of axon guidance in development of functional circuits. These studies will provide basic scientific basis for the therapeutic designs for neural circuit repair.
Signaling mechanisms for astrocyte polarization during glial scar formation after spinal cord injury
Spinal cord injury (SCI) can result in long-term loss of sensory and motor functions due to axon damage, gliosis, inflammation, and demyelination. Astrocytes constitute one of the principal components of the glial scar. We propose to test the hypothesis that Wnt/PCP signaling may be an important regulator of polarization of the reactive astrocytes after spinal cord injury, which may be important for glial scar formation and glial bridge formation.
Filed on February 07, 2019.
Tell us what you know about Yimin Zou's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Yimin Zou filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Yimin Zou | University of California, San Diego | Conflict of Interest | VersaChem, Inc. | Value cannot be readily determined |
| Yimin Zou | University of California, San Diego | Conflict of Interest | VersaChem, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.